Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing by Sokolenko, Anna P et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Hereditary Cancer in Clinical 
Practice
Open Access Case report
Large family with both parents affected by distinct BRCA1 
mutations: implications for genetic testing
Anna P Sokolenko1, Dmitry A Voskresenskiy1, Aglaya G Iyevleva1, 
Elena M Bit-Sava1, Nadezhda I Gutkina2, Maxim S Anisimenko2, Nathalia Yu 
Sherina1, Nathalia V Mitiushkina1, Yulia M Ulibina1, Olga S Yatsuk1, 
Olga A Zaitseva1, Evgeny N Suspitsin1, Alexandr V Togo1, Valery A Pospelov3, 
Sergey P Kovalenko2, Vladimir F Semiglazov1 and Evgeny N Imyanitov*1
Address: 1NN Petrov Institute of Oncology, St.-Petersburg, Russia, 2Institute of Molecular Biology and Biophysics, Novosibirsk, Russia and 
3Institute of Cytology, St.-Petersburg, Russia
Email: Anna P Sokolenko - annasokolenko@mail.ru; Dmitry A Voskresenskiy - dima_voskr@mail.ru; Aglaya G Iyevleva - aglayai@inbox.ru; 
Elena M Bit-Sava - bit-sava@mail.ru; Nadezhda I Gutkina - gutkinani@hotmail.com; Maxim S Anisimenko - max_anisimenko@mail.ru; 
Nathalia Yu Sherina - nata-lunna@mail.ru; Nathalia V Mitiushkina - nmmail@inbox.ru; YuliaMU l i b i n a-e l h i @ m a i l . ru; Olga S Yatsuk - olga-
yatsuk@mail.ru; Olga A Zaitseva - zayats_vorchun@mail.ru; Evgeny N Suspitsin - suspitsin@hotmail.com; Alexandr V Togo - a_togo@mail.ru; 
Valery A Pospelov - pospelov_v@mail.ru; Sergey P Kovalenko - skoval@sibmail.ru; Vladimir F Semiglazov - contact@niioncologii.ru; 
Evgeny N Imyanitov* - evgeny@imyanitov.spb.ru
* Corresponding author    
Abstract
Although the probability of both parents being affected by BRCA1 mutations is not negligible, such
families have not been systematically described in the literature. Here we present a large breast-
ovarian cancer family, where 3 sisters and 1 half-sister inherited maternal BRCA1 5382insC
mutation while the remaining 2 sisters carried paternal BRCA1 1629delC allele. No BRCA1
homozygous mutations has been detected, that is consistent with the data on lethality of BRCA1
knockout mice. This report exemplifies that the identification of a single cancer-predisposing
mutation within the index patient may not be sufficient in some circumstances. Ideally, all family
members affected by breast or ovarian tumor disease have to be subjected to the DNA testing,
and failure to detect the mutation in any of them calls for the search of the second cancer-
associated allele.
Case presentation
BRCA1 and BRCA2 mutations occur in approximately
0.2–1% healthy subjects, 5% non-selected breast cancer
(BC) patients, 15% consecutive ovarian cancer (OC)
cases, and 25% females with clinical features of hereditary
breast-ovarian cancer (HBOC) syndrome [1-8]. Given low
populational frequency and high penetrance of deleteri-
ous BRCA1 and BRCA2 mutations, only one of the parent
of the affected proband is usually suspected to contain
this genetic lesion. Nevertheless, the probability of both
parents being a carrier of BRCA1 or BRCA2 mutation is
not negligible. If we consider random healthy couples,
Published: 26 January 2009
Hereditary Cancer in Clinical Practice 2009, 7:2 doi:10.1186/1897-4287-7-2
Received: 9 September 2008
Accepted: 26 January 2009
This article is available from: http://www.hccpjournal.com/content/7/1/2
© 2009 Sokolenko et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Hereditary Cancer in Clinical Practice 2009, 7:2 http://www.hccpjournal.com/content/7/1/2
Page 2 of 4
(page number not for citation purposes)
this estimate would be equal to 0.2–1% × 0.2–1% =
0.0004–0.01% (i.e., 1:250000 - 1:10000). This probabil-
ity is significantly increased if we deal with already
affected females. Indeed, the most conservative calcula-
tion would imply that the chance to detect a mutation in
one of the parents of the patient is the same as in the
patient herself, whereas the probability for the remaining
parent to be affected by BRCA1 or BRCA2 defect is similar
to the populational frequency of the latter. Therefore,
approximately 0.01–0.05% (i.e., 1:10000 - 1:2000) of BC
patients, 0.03 – 0.15% (i.e., 1:3333-1:667) of OC
patients, and 0.05–0.25% (i.e., 1:2000 - 1:400) of women
with HOBC have both parents carrying BRCA1 or BRCA2
mutation. Coincident occurrence of BRCA1 heterozygos-
ity in mother and father is particularly likely if both par-
ents of the patient report a strong family history of the
Pedigree of the breast-ovarian cancer family with 2 BRCA1 mutations Figure 1
Pedigree of the breast-ovarian cancer family with 2 BRCA1 mutations. Circles and squares indicate females and 
males, respectively. Crossed symbols are used for deceased subjects; age at death is given after the letter "d", otherwise cur-
rent age is provided. Black circles correspond to females affected by breast or ovarian cancer; half-filled circles are used for yet 
healthy BRCA1 mutation carriers; gray symbols depict subjects with unknown or non-breast-ovarian tumors. BC – breast can-
cer; OC – ovarian cancer; age at cancer diagnosis is given in brackets. All tested subjects carried either BRCA1 5382insC or 
BRCA1 1629delC allele, i.e. missing information on the BRCA1 status indicates that DNA from this family member has not 
been analyzed. Index cases are designated by arrows (see the text).
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breast-ovarian cancer disease, however these situations
are exceptionally rare due to gender-specific penetrance of
BRCA1 and BRCA2 alterations and lack of explicit infor-
mation in the most of pedigrees.
Here we report an unique family with multiple affected
members and 2 distinct BRCA1 mutations identified.
Breast cancer patient III.9 was forwarded to a genetic
counselor in the year 2002 because of pronounced family
history (Fig. 1). She underwent DNA testing for Russian
founder mutations [8], however no genetic lesion has
been identified. DNA sequencing was not accessible to us
at that time, however, given an unusually strong family
history of breast-ovarian cancer and large number of yet
healthy female relatives, we desperately attempted to find
a facility who would agree to perform a full-length BRCA1
and BRCA2 analysis for this particular patient. Unfortu-
nately, this effort failed to succeed. The patient and her
only sister who accepted the invitation for genetic coun-
seling (III.5, healthy by then) were informed that their
family is likely to suffer from hereditary cancer syndrome,
and the failure to identify a causative mutation may be
related to current technical limitations. Therefore, we rec-
ommended tight diagnostic monitoring for BC and OC,
as well as consideration of comprehensive analysis of
breast cancer genes as soon as it becomes available. In the
year 2007, healthy female III.2 was forwarded to DNA
testing by her mammologist because of cancer family his-
tory concerns. "Founder" test-panel [8] revealed the pres-
ence of BRCA1 5382insC mutation, therefore she was
advised to consult with a cancer geneticist. Conversation
with this women revealed that she belonged to the same
family as the patient III.9, however she was unaware
about genetic counseling applied to her sisters III.9 and
III.5. Then, BRCA1 5382insC mutation testing was per-
formed for her affected mother (II.6, BC at age 66), her sis-
ters (III.4, healthy; III.5, affected by BC at age 52, i.e. after
the initial counseling in the year 2002; III.6, BC at age 35),
and her healthy 31-years-old nephew whose mother
(III.11) survived BC at age 35 but died from OC at 50. All
these relatives were found to carry BRCA1 5382insC
mutation, with the exception of BC patient III.6. Since
III.6 was already a second family member, who acquired
cancer disease but was negative for founder mutation test,
sequencing analysis was applied to DNA samples III.6 and
III.9; it identified second BRCA1 mutation, 1629delC.
Since 2 sisters from this family carry BRCA1 1629delC, it
is highly unlikely that these mutations appeared de novo;
instead, it is nearly certain that the father of these sisters
(II.5) was a carrier of this allele. We could not validate this
assumption, because this man died a long time ago. Sim-
ilarly, patient III.11 was likely to carry BRCA1 5382insC
mutation, but this could not be confirmed.
Homozygosity for BRCA1 inactivation was reported previ-
ously in a single human [9], although this observation
was later suggested to be a technical artifact [10]. We con-
ducted testing for both BRCA1 5382insC and 1629delC
alleles in all available DNA samples, and failed to detect
any biallelic defect. Taken together with the only available
publication on BRCA1 mutation occurring in both par-
ents [11] and a large body of evidence for early embryonic
lethality of BRCA1 knockout mice [12-14], our data pro-
vide additional support to the common statement on the
lack of viability of BRCA1-null homozygotes. This con-
trasts to the situation with another breast-ovarian cancer
gene, BRCA2, whose homozygous inactivation leads to
Fanconi anemia but is not absolutely lethal [15].
Conclusion
While families harboring both BRCA1 and BRCA2 muta-
tions have been repeatedly presented in the literature [16],
there is no systematic analysis of the pedigrees with both
parents carrying distinct alterations in the BRCA1 gene
[11]. Our observation calls for the same caution as was
formulated in a series of articles describing double muta-
tions for BRCA1 and BRCA2 [16]. First, in the communi-
ties with strong founder effect, relaxed criteria for subjects
selection should be used when considering the adminis-
tration of appropriate non-expensive PCR tests; it is highly
recommended that all BC and OC patients, and perhaps
even healthy middle-aged females, have to be offered the
opportunity of the DNA analysis [3,6,8,16]. Secondly, the
possibility of existence of disease phenocopies within the
same family has to be always remembered; therefore, fail-
ure to identify breast-ovarian cancer gene mutation in the
index case does not exclude the possibility of identifica-
tion of BRCA defect in other affected members of a given
pedigree. Ideally, all affected members of the family have
to undergo DNA testing at least for the presence of
founder mutations [16].
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